Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial of Testim(R) in Patients With Type II Diabetes
MALVERN, Pa., June 15 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL - News), a specialty pharmaceutical company, today reported top-line results from its Phase IV randomized trial of Testim® 1%, its topical testosterone gel, treatment in patients with Type II diabetes.

Login to read more...

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2010 UroToday ® All Rights Reserved